Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
F André, N Solovieff, F Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
P Sharma, W E Barlow, A K Godwin, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Oncogene
|
December 13, 2016
c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun
X Xie, T S Kaoud, R Edupuganti, et al.
Diabetologia
|
December 17, 2009
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study
R A DeFronzo, M A Banerji, G A Bray, et al.
Diabetes, Obesity & Metabolism
|
April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial
G A Bray, S R Smith, M A Banerji, et al.
Diabetologia
|
July 28, 2009
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans
A Monroy, S Kamath, A O Chavez, et al.
ESMO Open
|
November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open
|
August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
A Strahan, Q Jin, A S Raghavendra, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
F André, N Solovieff, F Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
P Sharma, W E Barlow, A K Godwin, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Oncogene
|
December 13, 2016
c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun
X Xie, T S Kaoud, R Edupuganti, et al.
Diabetologia
|
December 17, 2009
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study
R A DeFronzo, M A Banerji, G A Bray, et al.
Diabetes, Obesity & Metabolism
|
April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial
G A Bray, S R Smith, M A Banerji, et al.
Diabetologia
|
July 28, 2009
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans
A Monroy, S Kamath, A O Chavez, et al.
ESMO Open
|
November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open
|
August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
A Strahan, Q Jin, A S Raghavendra, et al.
Page
of 7